

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 63 (currently amended): A method for delivery of a hydrophobic drug to a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said hydrophobic drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy ultrasound at a frequency of 70-80 kilohertz to said selected site such that said hydrophobic drug is released from said hydrophobic core to said selected site.

Claim 64 (previously added): The method of claim 63 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

Claim 66 (previously amended): The method of claim 63 wherein said hydrophobic drug is an anthracycline.

Claim 67 (previously added): The method of claim 66 wherein said anthracycline is doxorubicin.

Claim 68 (previously added): The method of claim 66 wherein said anthracycline is ruboxyl.

Claim 74 (currently amended): A method for enhancing uptake of a hydrophobic drug by cells at a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said hydrophobic drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy ultrasound at a frequency of 70-80 kilohertz to said selected site such that said hydrophobic drug is released from said hydrophobic core and taken up by said cells.

Claim 75 (previously added): The method of claim 74 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

Claim 77 (previously amended): The method of claim 74  
wherein said hydrophobic drug is an anthracycline.

Claim 78 (previously added): The method of claim 77 wherein  
said anthracycline is doxorubicin.

Claim 79 (previously added): The method of claim 77 wherein  
said anthracycline is ruboxyl.

Claim 80 (currently amended): A method for reducing side  
effects in a patient from administration of a hydrophobic drug  
comprising:

(a) administering to said patient a composition comprising a  
micellar drug carrier comprising a hydrophobic core and an  
effective amount of said hydrophobic drug disposed in said  
hydrophobic core, wherein said micellar drug carrier is an AB-  
diblock copolymer; and

(b) applying ultrasonic energy ultrasound at a frequency of  
70-80 kilohertz to said patient such that said hydrophobic drug is  
released from said hydrophobic core.

Claim 81 (previously added): The method of claim 80 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

Claim 83 (previously amended): The method of claim 80 wherein said hydrophobic drug is an anthracycline.

Claim 84 (previously added): The method of claim 83 wherein said anthracycline is doxorubicin.

Claim 85 (previously added): The method of claim 83 wherein said anthracycline is ruboxyl.